Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03655613
Recruitment Status : Recruiting
First Posted : August 31, 2018
Last Update Posted : June 6, 2019
Sponsor:
Collaborators:
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Apollomics (Australia) Pty. Ltd.

Tracking Information
First Submitted Date  ICMJE July 17, 2018
First Posted Date  ICMJE August 31, 2018
Last Update Posted Date June 6, 2019
Actual Study Start Date  ICMJE September 5, 2018
Estimated Primary Completion Date September 15, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 30, 2018)
Dose Limiting Toxicities (Phase 1) [ Time Frame: Cycle 1 (up to 35 days) ]
Dose limiting toxicities (DLTs)
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03655613 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 30, 2018)
  • Adverse events [ Time Frame: First dose up to 90 days post last dose (up to approximately 2 years) ]
    Toxicity grading will be performed in accordance with NCI CTCAE, version 4.0. including immune related adverse events (irAEs)
  • Drug discontinuation due to adverse events [ Time Frame: First dose up to 90 days post last dose (up to approximately 2 years) ]
    Toxicity grading will be performed in accordance with NCI CTCAE, version 4.0. including immune related adverse events (irAEs)
  • Overall Response Rate [ Time Frame: Duration of study, performed at baseline, then every 8 weeks until objective disease progression (up to approximately 2 years) ]
    Tumor response will be assessed by immune related Response Evaluation Criteria in Solid Tumors (irRECIST)
  • Time to Response [ Time Frame: Duration of study, first dose to first response (up to approximately 2 years) ]
    Time to response is the time from first dose to date of first response (Partial response or Complete response)
  • Progression Free Survival [ Time Frame: Duration of study, performed at baseline, then every 8 weeks until objective disease progression at 6, 12, 18 and 24 months (up to approximately 2 years) ]
    Progression free survival will be collected on all enrolled subjects, defined as the time from first dose to death from any cause or first observed disease progression
  • Overall Survival [ Time Frame: Duration of study, performed every 8 weeks from enrollment to death from any cause at 6, 12, 18, 24 months (up to approximately 2 years) ]
    Overall survival will be estimated using the Kaplan-Meier method with the follow-up starting at the initiation of therapy until date of death
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Official Title  ICMJE A Phase 1/2 Dose Escalation and Expansion Study of Combination APL-501 or Nivolumab With APL-101 in Locally Advanced or Metastatic Hepatocellular and Renal Cell Carcinoma
Brief Summary

Study Design and Investigational Plan:

This is an open-label Phase 1/2 study to assess the safety and tolerability of combination PD-1 inhibitor (APL-501 or nivolumab) administered concomitantly with c-Met inhibitor (APL-101), to determine the recommended Phase 2 dose of the combination, and to obtain preliminary efficacy in HCC or RCC subjects with advanced or metastatic disease that have not been previously treated with a PD 1 inhibitor or a c-Met inhibitor. HCC subjects will receive the combination APL-501 plus APL-101 while RCC subjects will receive the combination nivolumab plus APL-101. In Phase 1, mandatory archival or fresh tumor biopsies will be collected. In Phase 2, a mandatory fresh tumor biopsy will be required for study entry and another fresh biopsy will be collected between Cycles 2 and 4. The frequency of administration of PD-1 inhibitors will be every 2 weeks starting in Cycle 1 on Day 8 and Day 22 of a 35-day cycle with all subsequent cycles on Day 1 and Day 15 of 28-day cycles. APL-101 will be administered orally every 12 hours continuously on an empty stomach.

Detailed Description For each potential subject, there is a 28-day screening and eligibility assessment period before enrollment; the first dose of study treatment will be administered on Day 1 of Cycle 1 (C1D1) (Safety population). Subjects will continue to receive their assigned treatment throughout the study until the occurrence of confirmed disease progression [progressive disease (PD)] by irRECIST, death, unacceptable treatment-related toxicity, or until the study is closed by the Sponsor. During the treatment period, study visits will occur on Day 1, Day 2, Day 8, Day 15, Day 22 of Cycle 1 and Day 1 and Day 15 of every subsequent cycle. Subjects who experience a response [Complete Response (CR), Partial Response (PR)] ≥ 2 cycles, PD 1 plus APL-101 combination will be continued until disease progression based on irRECIST. Subjects should receive a minimal of 2 cycles of PD-1 and APL-101 for adequate evaluation of response (Evaluable population). Discontinuation of PD-1 and APL-101 should occur upon determination of disease progression as determined by irRECIST, intolerable toxicity or when the risk/benefit ratio is no longer beneficial for the subjects as determined by the Principal Investigator, or upon subject withdrawal of consent. Upon permanent discontinuation of study treatment, there is a Treatment Termination visit and three monthly follow-up visits for a 90-day safety follow-up visit period. Subjects who drop out before they complete the first cycle of combination treatment for reasons other than toxicity will be replaced
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
(Phase 1) 3+3 dose escalation (Phase 2) Simon two-stage Minimax design
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Hepatocellular Carcinoma
  • Renal Cell Carcinoma
Intervention  ICMJE
  • Biological: APL-501
    Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
    Other Name: genolimzumab
  • Drug: APL-101
    Oral specific c-Met inhibitor
    Other Name: bozitinib
  • Biological: Nivolumab
    Fully human IgG4 monoclonal antibody against PD-1
    Other Name: Opdivo
Study Arms  ICMJE
  • Experimental: Arm A: Hepatocellular Carcinoma
    PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
    Interventions:
    • Biological: APL-501
    • Drug: APL-101
  • Experimental: Arm B: Renal Cell Carcinoma
    PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
    Interventions:
    • Drug: APL-101
    • Biological: Nivolumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 30, 2018)
119
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 15, 2020
Estimated Primary Completion Date September 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent.
  2. Men and women 18 years of age or older.
  3. Histologically confirmed advanced or metastatic hepatocellular carcinoma that progressed while receiving at least one previous line of systemic therapy, including sorafenib, or who are intolerant of or refused sorafenib treatment following progression on standard therapy including surgical and/or local regional therapies, or standard therapy considered ineffective, intolerable, or inappropriate or for which no effective standard therapy is available.
  4. Histologically confirmed advanced or metastatic renal cell carcinoma with clear cell component who received one or two prior lines of antiangiogenic therapy in addition to no more than three previous regimens of systemic therapy including cytokines and cytotoxic chemotherapy agents.
  5. Disease according to irRECIST that can be reliably and consistently followed.
  6. Documented disease progression during or after the last treatment regimen and within 6 months before study enrollment.
  7. Tumor amenable to tumor biopsy and subject agreeable to tumor biopsy at study entry and during therapy with study treatment.
  8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  9. Acceptable organ function.

Exclusion Criteria:

  1. History of severe hypersensitivity to mAbs, excipients of the APL-501, nivolumab, or APL-101.
  2. History of receiving treatment with any c-Met signaling pathway inhibitor (marketed or investigational agents).
  3. Prior therapy with anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or any other antibody targeting T cell co-stimulation pathways).
  4. Unwilling to swallow orally administered medication whole.
  5. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption (e.g., Crohn's, ulcerative colitis, active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
  6. Documented and/or known history of human immunodeficiency virus (HIV) for HCC and RCC subjects, or historical seropositive results consistent with active infection for hepatitis C virus (HCV) or hepatitis B virus (HBV) (RCC only).
  7. HCC subjects receiving active antiviral therapy for HCV.
  8. Active co-infection with HBV and HCV.
  9. Active co-infection with HBV and hepatitis D virus.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Shelly Nigam, MS 925.272.4090 shelly.nigam@apollomicsinc.com
Contact: Gavin Choy, PharmD 925.272.4090 gavin.choy@apollomicsinc.com
Listed Location Countries  ICMJE Australia,   New Zealand
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03655613
Other Study ID Numbers  ICMJE APOLLO
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Apollomics (Australia) Pty. Ltd.
Study Sponsor  ICMJE Apollomics (Australia) Pty. Ltd.
Collaborators  ICMJE
  • Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
  • Novotech (Australia) Pty Limited
Investigators  ICMJE
Study Chair: Fabio Benedetti, MD Apollomics (Australia) Pty. Ltd.
PRS Account Apollomics (Australia) Pty. Ltd.
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP